Mpox, Monkeypox clinical trials
The registry lists 72 studies for Mpox, Monkeypox across more than 10 countries. 30 are recruiting or about to start. 61 of them are mainly about Mpox, Monkeypox (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-01.
Get an email when these change. Save the Mpox, Monkeypox studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Institute of Tropical Medicine, Belgium (9) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (4) · ANRS, Emerging Infectious Diseases (3) · Osaka Metropolitan University (3) · Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" (3) · Assistance Publique - Hôpitaux de Paris (3) · Jean-Pierre Van geertruyden (2)
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest
- Nov 2026Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine · Assistance Publique - Hôpitaux de Paris
- Nov 2026Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells · Bavarian Nordic
- Dec 2026Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks · University of Birmingham
- Dec 2026Clinical and Biological Aspects of the MONKEYPOX Disease · Institut Pasteur
- Dec 2026Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination (MBOTE-TRAXX): Clinical Study to Monitor the Immunological Response Following Mpox Vaccination in the City of Kinshasa, Democratic Republic of the Congo · Institute of Tropical Medicine, Belgium
- Dec 2026Observational Mondkeypox Pregnancy Cohort · Robert Colebunders
- Feb 2027Understanding MPXV Viral Clearance, Transmission Dynamics, and Mpox Vaccine Effectiveness in West Africa : Guinea · London School of Hygiene and Tropical Medicine
- Feb 2027Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo · Shanghai Institute Of Biological Products
- Feb 2027Epidemiological and Pathophysiological Insights Through a Cross-sectional Survey (EPIC) · Institute of Tropical Medicine, Belgium
- Jun 2027A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa · BioNTech SE
Who these studies take
Of the 16 Mpox, Monkeypox studies recruiting now, 13 (81%) set no upper age limit and 2 (13%) stop at 75 or younger. 6 (38%) take children under 18. 0 (0%) are for women only and 1 (6%) for men only; 6 (38%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 5 (31%) | 6 (38%) |
| 18 | 15 (94%) | 16 (100%) |
| 30 | 15 (94%) | 16 (100%) |
| 40 | 15 (94%) | 16 (100%) |
| 50 | 15 (94%) | 16 (100%) |
| 65 | 13 (81%) | 14 (88%) |
| 75 | 13 (81%) | 14 (88%) |
| 85 | 12 (75%) | 13 (81%) |
Across all 72 studies, recruiting or not: 29% stop at 75 or younger and 28% at 65; 44% take children; 3% are for women only and 6% for men only; 53% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Mpox, Monkeypox studies take
Of 23 observational studies under Mpox, Monkeypox, half reached primary completion within 18 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Observational | 18 mo10–45 · 23 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
Studies
Recruiting first, then most recently updated. Showing 50 of 72. Browse all 72 → or search them.
- Evaluation of Effectiveness and Safety of LC16m8 Mpox Vaccine in the Democratic Republic of Congo (DRC)RecruitingNCT070934891 country
- New York City Observational Study of Mpox ImmunityEnrolling by invitationNCT056548831 country
- Smart Analysis and Decision-Making for Emerging Infectious DiseasesEnrolling by invitationNCT07678619Not applicable1 country
- A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in AfricaRecruitingNCT07379580Phase 22 countries
- Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort StudyRecruitingNCT055623231 country
- Tecovirimat (ST-246) Treatment for Orthopox Virus ExposureAvailableNCT02080767
- Validation of SDS-EDTA-Treated Chromatography Paper Strips for Mpox Sampling and Transport in DRCRecruitingNCT076340811 country
- Assessment of Immune Memory - Humoral and Cellular - in mPOX-infected Patients : an Ancillary Study of the ANRS0258s MOSAIC CohortNot yet recruitingNCT07592429Not applicable
- Understanding MPXV Viral Clearance, Transmission Dynamics, and Mpox Vaccine Effectiveness in West Africa : GuineaNot yet recruitingNCT075342671 country
- Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at RiskRecruitingNCT058799651 country
- Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.RecruitingNCT07377175Phase 11 country
- Prospective Follow-up After MVA-BN Booster VaccinationNot yet recruitingNCT073428291 country
- Neutralizing Power of Serum Antibodies - 2RecruitingNCT07085611Not applicable1 country
- Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the CongoNot yet recruitingNCT07253675Phase 2
- A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live VaccineRecruitingNCT06771479Phase 11 country
- Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of Congo (Part2)Enrolling by invitationNCT070677231 country
- Epidemiological and Clinical Characteristics of Mpox Outbreak in Equateur, the DR Congo (Part1)Enrolling by invitationNCT070558671 country
- Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of Congo (Part3)Enrolling by invitationNCT069847051 country
- Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN VaccineRecruitingNCT068858531 country
- Epidemiological and Pathophysiological Insights Through a Cross-sectional Survey (EPIC)RecruitingNCT068408601 country
- European Trial Into Mpox InfectionRecruitingNCT06156566Phase 48 countries
- Mpox Comprehensive Assessment for Responsive Immunisation in Emergency OutbreaksRecruitingNCT06887556Not applicable1 country
- DiagRaMIE Mpox Virus-RDC for the Diagnostic of MonkeypoxNot yet recruitingNCT068401971 country
- Mpox Biology, Outcome, Transmission and EpidemiologyEnrolling by invitationNCT066526461 country
- Observational, Prospective, Cohort Study of Mpox Infection in Brazil (NETPOX)RecruitingNCT057840381 country
- Observational Mondkeypox Pregnancy CohortNot yet recruitingNCT06442501
- Looking for Asymptomatic Mpox in a Population at High RiskRecruitingNCT063537371 country
- Mpox Prospective Observational Cohort StudyRecruitingNCT062912591 country
- Clinical and Biological Aspects of the MONKEYPOX DiseaseRecruitingNCT05627713Not applicable1 country
- Seroprevalence of Monkeypox Infection Among People Living With HIV and PrEP UsersNot yet recruitingNCT05922735
- Phase I Trial of an Investigational Small Pox MedicationCompletedNCT00728689Phase 11 country
- A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox VaccinesCompletedNCT05988203Phase 1/22 countries
- Performance Evaluation of Mpox Molecular POC DiagnosticsCompletedNCT076206001 country
- Mpox Paediatric and Adolescent Clinical StudyCompletedNCT059477866 countries
- Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCTActive, not recruitingNCT05745987Phase 43 countries
- Study of Tecovirimat for Human Mpox VirusTerminatedNCT05534984Phase 36 countries
- Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination (MBOTE-TRAXX): Clinical Study to Monitor the Immunological Response Following Mpox Vaccination in the City of Kinshasa, Democratic Republic of the CongoActive, not recruitingNCT07499739Phase 41 country
- Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus DiseaseActive, not recruitingNCT05597735Phase 33 countries
- An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa, DRCActive, not recruitingNCT06839989Phase 21 country
- Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIVTerminatedNCT060459231 country
- Investigating MPXV Viral Clearance in Mpox Cases and Secondary Attack Rate in ContactsCompletedNCT072673901 country
- Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRCActive, not recruitingNCT06844487Phase 31 country
- JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the CongoCompletedNCT02977715Phase 31 country
- Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox VaccineCompletedNCT05512949Phase 21 country
- Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production CellsActive, not recruitingNCT07199569Phase 21 country
- A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for MpoxCompletedNCT05740982Phase 22 countries
- Ocular Complications of Mpox in the Democratic Republic CongoCompletedNCT065798851 country
- Tecovirimat in Non-hospitalized Patients With MonkeypoxSuspendedNCT05534165Phase 31 country
- Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRCCompletedNCT05734508Phase 41 country
- Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRCActive, not recruitingNCT06844500Phase 31 country